Additionally, GLP-1 has neurological effects that decrease appetite, increase satiety, and reduce the desire for food [1]
Retatrutide targets three different receptors: GLP-1 (helps regulate appetite and blood sugar) GIP (supports insulin response) Glucagon (affects energy use and fat metabolism) By targeting all three, the medication delays how fast your stomach digests food, lowers your appetite, and ultimately reduces how much food you eat
There is no approved retatrutide dosage yet
At GLP-1R, EC50 values for cAMP accumulation are in the low nanomolar range
Patients should discuss these symptoms with a qualified clinician, especially if they are persistent, worsening, or uncomfortable
Your weight loss gets the attention, but these metabolic shifts are what reduce long-term cardiovascular and disease risk